YERBA MATE

OTHER NAME(S):

Chimarrao, Green Mate, Hervea, Ilex, Ilex paraguariensis, Jesuit's Brazil Tea, Jesuit's Tea, Maté, Maté Folium, Paraguay Tea, St. Bartholemew's Tea, Thé de Saint Barthélémy, Thé des Jésuites, Thé du Brésil, Thé du Paraguay, Yerbamate, Yerba Mate, Yerba Maté.<br/><br/>

Overview

Overview Information

Yerba mate is a plant. The leaves are used to make medicine.

Some people take yerba mate by mouth to relieve mental and physical tiredness (fatigue), as well as chronic fatigue syndrome (CFS). It is also taken by mouth for heart-related complaints including heart failure, irregular heartbeat, and low blood pressure.

Some people also take yerba mate by mouth to improve mood and depression; for diabetes; high cholesterol; weak bones (osteoporosis); to relieve headache and joint pains; to treat urinary tract infections (UTIs), and bladder and kidney stones; for weight loss; and as a laxative.

In foods, yerba mate is used to make a tea-like beverage.

How does it work?

Yerba mate contains caffeine and other chemicals which stimulate the brain, heart, muscles lining blood vessels, and other parts of the body.
Uses

Uses & Effectiveness?

Insufficient Evidence for

  • Mental function. Early research shows that drinking a beverage containing yerba mate does not improve memory, reaction time, or mental accuracy in healthy females.
  • Diabetes. Early research shows that drinking yerba mate tea three times daily for 60 days can lower blood sugar in people with type 2 diabetes.
  • High cholesterol (hyperlipidemia). Early research shows that drinking tea containing yerba mate three times daily for 40 days can lower total cholesterol and low-density lipoprotein (LDL or “bad”) cholesterol, and increase high-density lipoprotein (HDL or “bad”) cholesterol, in people with high cholesterol. This includes people already taking statin drugs.
  • Obesity. Early research shows that taking yerba mate by mouth might decrease fat and cause weight loss when used alone or in combination with guarana and damiana.
  • Weak bones (osteoporosis). Drinking yerba mate tea every day for at least 4 years might reduce the rate of bone loss in postmenopausal women.
  • Prediabetes. Early research shows that drinking yerba mate tea three times daily for 60 days does not reduce fasting blood sugar in people with prediabetes. However, it might reduce glycated hemoglobin (HbA1C), a measure of average blood sugar.
  • Chronic fatigue syndrome (CFS).
  • Constipation.
  • Depression.
  • Fluid retention.
  • Headaches.
  • Heart conditions.
  • Kidney and bladder stones.
  • Low blood pressure (hypotension).
  • Mental and physical tiredness (fatigue).
  • Urinary tract infections (UTIs).
  • Other conditions.
More evidence is needed to rate the effectiveness of yerba mate for these uses.

Side Effects

Side Effects & Safety

Yerba mate is POSSIBLY SAFE for most people, when taken by mouth for short periods of time. Yerba mate contains caffeine, which in some people can cause side effects such as inability to sleep (insomnia), nervousness and restlessness, upset stomach, nausea and vomiting, increased heart rate and breathing, high blood pressure, headache, ringing in the ears, irregular heartbeats, and other side effects.

Yerba mate is POSSIBLY UNSAFE when taken in large amounts or for long periods of time. It increases the risk of esophageal cancer, kidney cancer, stomach cancer, bladder cancer, cervical cancer, prostate cancer, lung cancer, and possibly laryngeal or mouth cancer. This risk is especially high for people who smoke or drink alcohol.

Yerba mate is LIKELY UNSAFE when taken in very large amounts, due to its caffeine content.

Special Precautions & Warnings:

Children: Yerba mate is POSSIBLY UNSAFE for children when taken by mouth. Yerba mate is linked with an increased risk of esophageal cancer, kidney cancer, stomach cancer, bladder cancer, cervical cancer, prostate cancer, lung cancer, and possibly laryngeal or mouth cancer.

Pregnancy and breast-feeding: Yerba mate is POSSIBLY UNSAFE when taken by mouth during pregnancy. One concern is that using yerba mate seems to increase the risk of getting cancer. It’s not known whether that risk is transferred to the developing fetus. Another concern is the caffeine content of yerba mate. Caffeine crosses the placenta and enters the fetus’ bloodstream, producing caffeine levels in the fetus that resemble the caffeine level in the mother. In general, mothers should avoid consuming more than 300 mg of caffeine daily; that’s about 3 cups of coffee or tea. Infants born to mothers who consume a lot of caffeine during pregnancy sometimes show symptoms of caffeine withdrawal after birth. High doses of caffeine have also been linked with miscarriage, premature delivery, and low birth weight. However, researchers studied mothers who drank yerba mate tea during pregnancy and found no strong link between drinking yerba mate and premature delivery or small birth weight. But this study has been criticized because it did not consider the amount of yerba mate or caffeine used by the mothers; it looked only at how often they used yerba mate.

Yerba mate is also POSSIBLY UNSAFE during breast-feeding. It is not known whether the cancer-causing chemicals in yerba mate pass into breast milk, but that is a concern. The caffeine in yerba mate is also a problem. It might cause irritability and increased bowel movements in nursing infants.

Alcoholism: Heavy alcohol use combined with long-term yerba mate use increases the risk of cancer from 3-fold to 7-fold.

Anxiety disorders: The caffeine in yerba mate might make anxiety disorders worse.

Bleeding disorders: Caffeine might slow clotting. As a result, there is a concern that the caffeine in yerba mate might make bleeding disorders worse. But so far, this effect has not been reported in people.

Heart conditions: Caffeine in yerba mate can cause irregular heartbeats in certain people. If you have a heart condition, discuss using yerba mate with your healthcare provider.

Diabetes: Some research shows that the caffeine in yerba mate may affect the way people with diabetes process sugar and may complicate blood sugar control. There is also some interesting research that shows caffeine may make the warning symptoms of low blood sugar in people with type 1 diabetes more noticeable. Some studies show that the symptoms of low blood sugar are more intense when they start in the absence of caffeine, but as low blood sugar continues, symptoms are greater with caffeine. This might increase the ability of people with diabetes to detect and treat low blood sugar. However, the downside is that caffeine might actually increase the number of low-sugar episodes. If you have diabetes, talk with your healthcare provider before using yerba mate.

Diarrhea: Yerba mate contains caffeine. The caffeine in yerba mate, especially when taken in large amounts, can worsen diarrhea.

Glaucoma: Using yerba mate increases the pressure inside the eye due to the caffeine it contains. The increase in pressure occurs within 30 minutes and lasts for at least 90 minutes. If you have glaucoma, discuss your use of yerba mate with your healthcare provider.

High blood pressure: The caffeine in yerba mate might increase blood pressure in people with high blood pressure. Consuming 250 mg of caffeine can increase blood pressure in healthy people, but this doesn't seem to happen in people who use caffeine all the time.

Irritable bowel syndrome (IBS): Yerba mate contains caffeine. The caffeine in yerba mate, especially when taken in large amounts, can worsen diarrhea and might worsen symptoms of IBS.

Weak bones (osteoporosis): Some researchers have found that postmenopausal women who drink a liter or more daily of a traditional South American yerba mate tea have higher bone density. However, the caffeine in yerba mate tends to flush calcium out of the body in the urine. This can contribute to weak bones. For this reason, many experts recommend that caffeine intake be limited to less than 300 mg per day (approximately 2-3 cups of yerba mate). Taking extra calcium may help to make up for the calcium that is flushed out.

There are some women who are at special risk for weak bones. These women have an inherited condition that makes it hard for them to use vitamin D properly. Vitamin D works with calcium to build strong bones. These women should be especially careful to limit the amount of caffeine they get from yerba mate as well as other sources.

Smoking: The risk of getting cancer is 3 to 7 times higher in people who smoke and use yerba mate for long periods of time.

Interactions

Interactions?

Major Interaction

Do not take this combination

!
  • Amphetamines interacts with YERBA MATE

    Stimulant drugs such as amphetamines speed up the nervous system. By speeding up the nervous system, stimulant medications can make you feel jittery and increase your heart rate. The caffeine in mate might also speed up the nervous system. Taking mate along with stimulant drugs might cause serious problems including increased heart rate and high blood pressure. Avoid taking stimulant drugs along with mate.

  • Cocaine interacts with YERBA MATE

    Stimulant drugs such as cocaine speed up the nervous system. By speeding up the nervous system, stimulant medications can make you feel jittery and increase your heart rate. The caffeine in mate might also speed up the nervous system. Taking mate along with stimulant drugs might cause serious problems including increased heart rate and high blood pressure. Avoid taking stimulant drugs along with mate.

  • Ephedrine interacts with YERBA MATE

    Stimulant drugs speed up the nervous system. Caffeine (contained in mate) and ephedrine are both stimulant drugs. Taking caffeine along with ephedrine might cause too much stimulation and sometimes serious side effects and heart problems. Do not take caffeine-containing products and ephedrine at the same time.

Moderate Interaction

Be cautious with this combination

!
  • Adenosine (Adenocard) interacts with YERBA MATE

    Mate contains caffeine. The caffeine in mate might block the affects of adenosine (Adenocard). Adenosine (Adenocard) is often used by doctors to do a test on the heart. This test is called a cardiac stress test. Stop consuming mate or other caffeine-containing products at least 24 hours before a cardiac stress test.

  • Antibiotics (Quinolone antibiotics) interacts with YERBA MATE

    The body breaks down caffeine to get rid of it. Some antibiotics might decrease how quickly the body breaks down caffeine. Taking these antibiotics along with mate can increase the risk of side effects including jitteriness, headache, increased heart rate, and other side effects.<br/><br/> Some antibiotics that decrease how quickly the body breaks down caffeine include ciprofloxacin (Cipro), enoxacin (Penetrex), norfloxacin (Chibroxin, Noroxin), sparfloxacin (Zagam), trovafloxacin (Trovan), and grepafloxacin (Raxar).

  • Cimetidine (Tagamet) interacts with YERBA MATE

    Mate contains caffeine. The body breaks down caffeine to get rid of it. Cimetidine (Tagamet) can decrease how quickly your body breaks down caffeine. Taking cimetidine (Tagamet) along with mate might increase the chance of caffeine side effects including jitteriness, headache, fast heartbeat, and others.

  • Clozapine (Clozaril) interacts with YERBA MATE

    The body breaks down clozapine (Clozaril) to get rid of it. The caffeine in mate seems to decrease how quickly the body breaks down clozapine (Clozaril). Taking mate along with clozapine (Clozaril) can increase the effects and side effects of clozapine (Clozaril).

  • Dipyridamole (Persantine) interacts with YERBA MATE

    Mate contains caffeine. The caffeine in mate might block the affects of dipyridamole (Persantine). Dipyridamole (Persantine) is often used by doctors to do a test on the heart. This test is called a cardiac stress test. Stop consuming mate or other caffeine-containing products at least 24 hours before a cardiac stress test.

  • Disulfiram (Antabuse) interacts with YERBA MATE

    The body breaks down caffeine to get rid of it. Disulfiram (Antabuse) can decrease how quickly the body gets rid of caffeine. Taking mate (which contains caffeine) along with disulfiram (Antabuse) might increase the effects and side effects of caffeine including jitteriness, hyperactivity, irritability, and others.

  • Estrogens interacts with YERBA MATE

    The body breaks down caffeine (contained in mate) to get rid of it. Estrogens can decrease how quickly the body breaks down caffeine. Decreasing the breakdown of caffeine can cause jitteriness, headache, fast heartbeat, and other side effects. If you take estrogens limit your caffeine intake.<br/><br/> Some estrogen pills include conjugated equine estrogens (Premarin), ethinyl estradiol, estradiol, and others.

  • Fluvoxamine (Luvox) interacts with YERBA MATE

    The body breaks down the caffeine in mate to get rid of it. Fluvoxamine (Luvox) can decrease how quickly the body breaks down caffeine. Taking mate along with fluvoxamine (Luvox) might cause too much caffeine in the body, and increase the effects and side effects of mate.

  • Lithium interacts with YERBA MATE

    Your body naturally gets rid of lithium. The caffeine in mate can increase how quickly your body gets rid of lithium. If you take products that contain caffeine and you take lithium, stop taking caffeine products slowly. Stopping mate too quickly can increase the side effects of lithium.

  • Medications for depression (MAOIs) interacts with YERBA MATE

    The caffeine in mate can stimulate the body. Some medications used for depression can also stimulate the body. Drinking mate and taking some medications for depression might cause too much stimulation to the body and serious side effects including fast heartbeat, high blood pressure, nervousness, and others could occur.<br/><br/> Some of these medications used for depression include phenelzine (Nardil), tranylcypromine (Parnate), and others.

  • Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with YERBA MATE

    Mate contains caffeine. Caffeine might slow blood clotting. Taking mate along with medications that also slow clotting might increase the chances of bruising and bleeding.<br/><br/> Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.

  • Nicotine interacts with YERBA MATE

    Stimulant drugs such as nicotine speed up the nervous system. By speeding up the nervous system, stimulant medications can make you feel jittery and increase your heart rate. The caffeine in mate might also speed up the nervous system. Taking mate along with stimulant drugs might cause serious problems including increased heart rate and high blood pressure. Avoid taking stimulant drugs along with mate.

  • Pentobarbital (Nembutal) interacts with YERBA MATE

    The stimulant effects of the caffeine in mate can block the sleep-producing effects of pentobarbital.

  • Phenylpropanolamine interacts with YERBA MATE

    Mate contains caffeine. Caffeine can stimulate the body. Phenylpropanolamine can also stimulate the body. Taking mate and phenylpropanolamine together might cause too much stimulation and increase heartbeat and blood pressure and cause nervousness.

  • Riluzole (Rilutek) interacts with YERBA MATE

    The body breaks down riluzole (Rilutek) to get rid of it. Taking mate can decrease how fast the body breaks down riluzole (Rilutek) and increase the effects and side effects of riluzole.

  • Theophylline interacts with YERBA MATE

    Mate contains caffeine. Caffeine works similarly to theophylline. Caffeine can also decrease how quickly the body gets rid of theophylline. Taking mate along with theophylline might increase the effects and side effects of theophylline.

  • Verapamil (Calan, Covera, Isoptin, Verelan) interacts with YERBA MATE

    The body breaks down the caffeine in mate to get rid of it. Verapamil (Calan, Covera, Isoptin, Verelan) can decrease how quickly the body gets rid of caffeine. Drinking mate and taking verapamil (Calan, Covera, Isoptin, Verelan) can increase the risk of side effects for caffeine including jitteriness, headache, and an increased heartbeat.

Minor Interaction

Be watchful with this combination

!
  • Alcohol interacts with YERBA MATE

    The body breaks down the caffeine in mate to get rid of it. Alcohol can decrease how quickly the body breaks down caffeine. Taking mate along with alcohol might cause too much caffeine in the bloodstream and caffeine side effects including jitteriness, headache, and fast heartbeat.

  • Birth control pills (Contraceptive drugs) interacts with YERBA MATE

    The body breaks down the caffeine in mate to get rid of it. Birth control pills can decrease how quickly the body breaks down caffeine. Taking mate along with birth control pills can cause jitteriness, headache, fast heartbeat, and other side effects.<br/><br/> Some birth control pills include ethinyl estradiol and levonorgestrel (Triphasil), ethinyl estradiol and norethindrone (Ortho-Novum 1/35, Ortho-Novum 7/7/7), and others.

  • Fluconazole (Diflucan) interacts with YERBA MATE

    Mate contains caffeine. The body breaks down caffeine to get rid of it. Fluconazole (Diflucan) might decrease how quickly the body gets rid of caffeine. This could cause caffeine to stay in the body too long and increase the risk of side effects such as nervousness, anxiety, and insomnia.

  • Medications for diabetes (Antidiabetes drugs) interacts with YERBA MATE

    Mate might increase blood sugar. Diabetes medications are used to lower blood sugar. By increasing blood sugar, mate might decrease the effectiveness of diabetes medications. Monitor your blood sugar closely. The dose of your diabetes medication might need to be changed.<br/><br/> Some medications used for diabetes include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), chlorpropamide (Diabinese), glipizide (Glucotrol), tolbutamide (Orinase), and others.

  • Mexiletine (Mexitil) interacts with YERBA MATE

    Mate contains caffeine. The body breaks down caffeine to get rid of it. Mexiletine (Mexitil) can decrease how quickly the body breaks down caffeine. Taking Mexiletine (Mexitil) along with mate might increase the caffeine effects and side effects of mate.

  • Terbinafine (Lamisil) interacts with YERBA MATE

    The body breaks down caffeine (contained in mate) to get rid of it. Terbinafine (Lamisil) can decrease how fast the body gets rid of caffeine and increase the risk of side effects including jitteriness, headache, increased heartbeat, and other effects.

Dosing

Dosing

The appropriate dose of mate depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for mate. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References

REFERENCES:

  • Arcari, D. P., Bartchewsky, W., dos Santos, T. W., Oliveira, K. A., Funck, A., Pedrazzoli, J., de Souza, M. F., Saad, M. J., Bastos, D. H., Gambero, A., Carvalho, Pde O., and Ribeiro, M. L. Antiobesity effects of yerba mate extract (Ilex paraguariensis) in high-fat diet-induced obese mice. Obesity.(Silver.Spring) 2009;17(12):2127-2133. View abstract.
  • Bracesco, N., Sanchez, A. G., Contreras, V., Menini, T., and Gugliucci, A. Recent advances on Ilex paraguariensis research: Minireview. J Ethnopharmacol. 6-26-2010; View abstract.
  • Clausen, T. Hormonal and pharmacological modification of plasma potassium homeostasis. Fundam.Clin Pharmacol 2010;24(5):595-605. View abstract.
  • de Morais, E. C., Stefanuto, A., Klein, G. A., Boaventura, B. C., de, Andrade F., Wazlawik, E., Di Pietro, P. F., Maraschin, M., and da Silva, E. L. Consumption of yerba mate ( Ilex paraguariensis ) improves serum lipid parameters in healthy dyslipidemic subjects and provides an additional LDL-cholesterol reduction in individuals on statin therapy. J Agric.Food Chem. 9-23-2009;57(18):8316-8324. View abstract.
  • Dickel, M. L., Rates, S. M., and Ritter, M. R. Plants popularly used for loosing weight purposes in Porto Alegre, South Brazil. J Ethnopharmacol 1-3-2007;109(1):60-71. View abstract.
  • Ernest, D., Chia, M., and Corallo, C. E. Profound hypokalaemia due to Nurofen Plus and Red Bull misuse. Crit Care Resusc. 2010;12(2):109-110. View abstract.
  • Fonseca, C. A., Otto, S. S., Paumgartten, F. J., and Leitao, A. C. Nontoxic, mutagenic, and clastogenic activities of Mate-Chimarrao (Ilex paraguariensis). J.Environ.Pathol.Toxicol.Oncol. 2000;19(4):333-346. View abstract.
  • Gorzalczany, S., Filip, R., Alonso, M. R., Mino, J., Ferraro, G. E., and Acevedo, C. Choleretic effect and intestinal propulsion of 'mate' (Ilex paraguariensis) and its substitutes or adulterants. J Ethnopharmacol. 2001;75(2-3):291-294. View abstract.
  • Hussein, G. M., Matsuda, H., Nakamura, S., Akiyama, T., Tamura, K., and Yoshikawa, M. Protective and ameliorative effects of mate (Ilex paraguariensis) on metabolic syndrome in TSOD mice. Phytomedicine. 12-15-2011;19(1):88-97. View abstract.
  • Jeppesen, U., Loft, S., Poulsen, H. E., and Brsen, K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6(3):213-222. View abstract.
  • Klein, G. A., Stefanuto, A., Boaventura, B. C., de Morais, E. C., Cavalcante, Lda S., de, Andrade F., Wazlawik, E., Di Pietro, P. F., Maraschin, M., and da Silva, E. L. Mate tea (Ilex paraguariensis) improves glycemic and lipid profiles of type 2 diabetes and pre-diabetes individuals: a pilot study. J Am Coll.Nutr. 2011;30(5):320-332. View abstract.
  • Martin, I., Lopez-Vilchez, M. A., Mur, A., Garcia-Algar, O., Rossi, S., Marchei, E., and Pichini, S. Neonatal withdrawal syndrome after chronic maternal drinking of mate. Ther Drug Monit. 2007;29(1):127-129. View abstract.
  • Martinet, A., Hostettmann, K., and Schutz, Y. Thermogenic effects of commercially available plant preparations aimed at treating human obesity. Phytomedicine. 1999;6(4):231-238. View abstract.
  • Martins, F., Noso, T. M., Porto, V. B., Curiel, A., Gambero, A., Bastos, D. H., Ribeiro, M. L., and Carvalho, Pde O. Mate tea inhibits in vitro pancreatic lipase activity and has hypolipidemic effect on high-fat diet-induced obese mice. Obesity.(Silver.Spring) 2010;18(1):42-47. View abstract.
  • Matsumoto, R. L., Bastos, D. H., Mendonca, S., Nunes, V. S., Bartchewsky, W., Ribeiro, M. L., and de Oliveira, Carvalho P. Effects of mate tea (Ilex paraguariensis) ingestion on mRNA expression of antioxidant enzymes, lipid peroxidation, and total antioxidant status in healthy young women. J Agric.Food Chem. 3-11-2009;57(5):1775-1780. View abstract.
  • Meyer, K. and Ball, P. Psychological and Cardiovascular Effects of Guarana and Yerba Mate: A Comparison with Coffee. Revista Interamericana de Psicologia 2004;38(1):87-94.
  • Milioli, E. M., Cologni, P., Santos, C. C., Marcos, T. D., Yunes, V. M., Fernandes, M. S., Schoenfelder, T., and Costa-Campos, L. Effect of acute administration of hydroalcohol extract of Ilex paraguariensis St Hilaire (Aquifoliaceae) in animal models of Parkinson's disease. Phytother.Res 2007;21(8):771-776. View abstract.
  • Miranda, D. D., Arcari, D. P., Pedrazzoli, J., Jr., Carvalho, Pde O., Cerutti, S. M., Bastos, D. H., and Ribeiro, M. L. Protective effects of mate tea (Ilex paraguariensis) on H2O2-induced DNA damage and DNA repair in mice. Mutagenesis 2008;23(4):261-265. View abstract.
  • Mosimann, A. L., Wilhelm-Filho, D., and da Silva, E. L. Aqueous extract of Ilex paraguariensis attenuates the progression of atherosclerosis in cholesterol-fed rabbits. Biofactors 2006;26(1):59-70. View abstract.
  • Pang, J., Choi, Y., and Park, T. Ilex paraguariensis extract ameliorates obesity induced by high-fat diet: potential role of AMPK in the visceral adipose tissue. Arch.Biochem.Biophys. 8-15-2008;476(2):178-185. View abstract.
  • Pittler, M. H. and Ernst, E. Dietary supplements for body-weight reduction: a systematic review. Am.J.Clin Nutr. 2004;79(4):529-536. View abstract.
  • Pittler, M. H., Schmidt, K., and Ernst, E. Adverse events of herbal food supplements for body weight reduction: systematic review. Obes.Rev. 2005;6(2):93-111. View abstract.
  • Rigato, I., Blarasin, L., and Kette, F. Severe hypokalemia in 2 young bicycle riders due to massive caffeine intake. Clin J Sport Med. 2010;20(2):128-130. View abstract.
  • ROTH, J. L. Clinical evaluation of the caffeine gastric analysis in duodenal ulcer patients. Gastroenterology 1951;19(2):199-215. View abstract.
  • Simmonds, M. J., Minahan, C. L., and Sabapathy, S. Caffeine improves supramaximal cycling but not the rate of anaerobic energy release. Eur.J Appl Physiol 2010;109(2):287-295. View abstract.
  • Smits, P., Lenders, J. W., and Thien, T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. Clin.Pharmacol.Ther. 1990;48(4):410-418. View abstract.
  • Smits, P., Temme, L., and Thien, T. The cardiovascular interaction between caffeine and nicotine in humans. Clin Pharmacol Ther 1993;54(2):194-204. View abstract.
  • Sugimoto, S., Nakamura, S., Yamamoto, S., Yamashita, C., Oda, Y., Matsuda, H., and Yoshikawa, M. Brazilian natural medicines. III. structures of triterpene oligoglycosides and lipase inhibitors from mate, leaves of ilex paraguariensis. Chem.Pharm.Bull.(Tokyo) 2009;57(3):257-261. View abstract.
  • Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-8. View abstract.
  • Acheson KJ, Gremaud G, Meirim I, et al. Metabolic effects of caffeine in humans: lipid oxidation or futile cycling? Am J Clin Nutr 2004;79:40-6. View abstract.
  • Ali M, Afzal M. A potent inhibitor of thrombin stimulated platelet thromboxane formation from unprocessed tea. Prostaglandins Leukot Med 1987;27:9-13. View abstract.
  • American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89. View abstract.
  • Andersen T, Fogh J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J Hum Nutr Diet 2001;14:243-50. View abstract.
  • Aqel RA, Zoghbi GJ, Trimm JR, et al. Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease. Am J Cardiol 2004;93:343-6. View abstract.
  • Ardlie NG, Glew G, Schultz BG, Schwartz CJ. Inhibition and reversal of platelet aggregation by methyl xanthines. Thromb Diath Haemorrh 1967;18:670-3. View abstract.
  • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. Ann Pharmacother 2002;36:992-5.. View abstract.
  • Azcona O, Barbanoi MJ, Torrent J, Jane F. Evaluation of the central effects of alcohol and caffeine interaction. Br J Clin Pharmacol 1995;40:393-400. View abstract.
  • Bara AI, Barley EA. Caffeine for asthma. Cochrane Database Syst Rev 2001;4:CD001112.. View abstract.
  • Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. Med Sci Sports Exerc 2001;33:1399-403. View abstract.
  • Benowitz NL, Osterloh J, Goldschlager N, et al. Massive catecholamine release from caffeine poisoning. JAMA 1982;248:1097-8. View abstract.
  • Broughton LJ, Rogers HJ. Decreased systemic clearance of caffeine due to cimetidine. Br J Clin Pharmacol 1981;12:155-9. View abstract.
  • Brown NJ, Ryder D, Branch RA. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clin Pharmacol Ther 1991;50:363-71. View abstract.
  • Cannon ME, Cooke CT, McCarthy JS. Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products. Med J Aust 2001;174:520-1. View abstract.
  • Carbo M, Segura J, De la Torre R, et al. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther 1989;45:234-40. View abstract.
  • Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000;39:127-53. View abstract.
  • Cesana M, Broccali G, Imbimbo BP, Crema A. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration. Int J Clin Pharmacol Ther Toxicol 1991:29:133-8. View abstract.
  • Chiu KM. Efficacy of calcium supplements on bone mass in postmenopausal women. J Gerontol A Biol Sci Med Sci 1999;54:M275-80. View abstract.
  • Chou T. Wake up and smell the coffee. Caffeine, coffee, and the medical consequences. West J Med 1992;157:544-53. View abstract.
  • Chroscinska-Krawczyk, M., Jargiello-Baszak, M., Walek, M., Tylus, B., and Czuczwar, S. J. Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. Pharmacol.Rep. 2011;63(1):12-18. View abstract.
  • Conforti AS, Gallo ME, Saraví FD. Yerba Mate (Ilex paraguariensis) consumption is associated with higher bone mineral density in postmenopausal women. Bone 2012;50:9-13. View abstract.
  • De Stefani E, Correa P, Fierro L, et al. Black tobacco, mate, and bladder cancer. A case-control study from Uruguay. Cancer 1991;67:536-40. View abstract.
  • De Stefani E, Fierro L, Correa P, et al. Mate drinking and risk of lung cancer in males: a case-control study from Uruguay. Cancer Epidemiol Biomarkers Prev 1996;5:515-9. View abstract.
  • De Stefani E, Fierro L, Mendilaharsu M, et al. Meat intake, 'mate' drinking and renal cell cancer in Uruguay: a case-control study. Br J Cancer 1998;78:1239-43. View abstract.
  • Dews PB, Curtis GL, Hanford KJ, O'Brien CP. The frequency of caffeine withdrawal in a population-based survey and in a controlled, blinded pilot experiment. J Clin Pharmacol 1999;39:1221-32. View abstract.
  • Dews PB, O'Brien CP, Bergman J. Caffeine: behavioral effects of withdrawal and related issues. Food Chem Toxicol 2002;40:1257-61. View abstract.
  • DiPiro JT, Talbert RL, Yee GC, et al; eds. Pharmacotherapy: A pathophysiologic approach. 4th ed. Stamford, CT: Appleton & Lange, 1999.
  • Dreher HM. The effect of caffeine reduction on sleep quality and well-being in persons with HIV. J Psychosom Res 2003;54:191-8.. View abstract.
  • Durrant KL. Known and hidden sources of caffeine in drug, food, and natural products. J Am Pharm Assoc 2002;42:625-37. View abstract.
  • Esmelindro AA, Girardi Jdos S, Mossi A, et al. Influence of agronomic variables on the composition of mate tea leaves (Ilex paraguariensis) extracts obtained from CO2 extraction at 30 degrees C and 175 bar. J Agric Food Chem 2004;52:1990-5. View abstract.
  • FDA. Proposed rule: dietary supplements containing ephedrine alkaloids. Available at: www.verity.fda.gov (Accessed 25 January 2000).
  • Ferrini RL, Barrett-Connor E. Caffeine intake and endogenous sex steroid levels in postmenopausal women. The Rancho Bernardo Study. Am J Epidemiol 1996:144:642-4. View abstract.
  • Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999.
  • File SE, Bond AJ, Lister RG. Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. J Clin Psychopharmacol 1982;2:102-6. View abstract.
  • For Dieter, Nearly the Ultimate Loss. The Washington Post. Available at: http://www.washingtonpost.com/archive/politics/2000/03/19/for-dieter-nearly-the-ultimate-loss/c0f07474-489d-4f44-bc17-1f1367c956ae/ (Accessed 19 March 2000).
  • Forrest WH Jr, Bellville JW, Brown BW Jr. The interaction of caffeine with pentobarbital as a nighttime hypnotic. Anesthesiology 1972;36:37-41. View abstract.
  • Gambero A and Ribeiro ML. The positive effects of yerba mate (Ilex paraguariensis) in obesity. Nutrients. 2015;7(2):730-50. View abstract.
  • Gasior, M., Borowicz, K., Buszewicz, G., Kleinrok, Z., and Czuczwar, S. J. Anticonvulsant activity of phenobarbital and valproate against maximal electroshock in mice during chronic treatment with caffeine and caffeine discontinuation. Epilepsia 1996;37(3):262-268. View abstract.
  • Gasior, M., Swiader, M., Przybylko, M., Borowicz, K., Turski, W. A., Kleinrok, Z., and Czuczwar, S. J. Felbamate demonstrates low propensity for interaction with methylxanthines and Ca2+ channel modulators against experimental seizures in mice. Eur.J Pharmacol 7-10-1998;352(2-3):207-214. View abstract.
  • Goldenberg D, Golz A, Joachims HZ. The beverage mate: a risk factor for cancer of the head and neck. Head Neck 2003;25:595-601. View abstract.
  • Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. Am J Hosp Pharm 1979;36:754-7. View abstract.
  • Grandjean AC, Reimers KJ, Bannick KE, Haven MC. The effect of caffeinated, non-caffeinated, caloric and non-caloric beverages on hydration. J Am Coll Nutr 2000;19:591-600.. View abstract.
  • Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2000;49:59-63. View abstract.
  • Haller CA, Benowitz NL, Jacob P 3rd. Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med 2005;118:998-1003.. View abstract.
  • Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8. View abstract.
  • Harder S, Fuhr U, Staib AH, Wolff T. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 1989;87:89S-91S. View abstract.
  • Harder S, Staib AH, Beer C, et al. 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol 1988;35:651-6. View abstract.
  • Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989;33:474-8. View abstract.
  • Holmgren P, Norden-Pettersson L, Ahlner J. Caffeine fatalities--four case reports. Forensic Sci Int 2004;139:71-3. View abstract.
  • Horner NK, Lampe JW. Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness. J Am Diet Assoc 2000;100:1368-80. View abstract.
  • Howell LL, Coffin VL, Spealman RD. Behavioral and physiological effects of xanthines in nonhuman primates. Psychopharmacology (Berl) 1997;129:1-14. View abstract.
  • Hsu CK, Leo P, Shastry D, et al. Anticholinergic poisoning associated with herbal tea. Arch Intern Med 1995;155:2245-8. View abstract.
  • Infante S, Baeza ML, Calvo M, et al. Anaphylaxis due to caffeine. Allergy 2003;58:681-2. View abstract.
  • Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington, DC: National Academy Press, 2001. Available at: http://books.nap.edu/books/0309082587/html/index.html.
  • International Agency for Research on Cancer (IARC). IARC monographs evaluate drinking coffee, mate, and very hot beverages. https://www.iarc.fr/en/media-centre/pr/2016/pdfs/pr244_E.pdf. Accessed November 1, 2017.
  • Jankiewicz, K., Chroscinska-Krawczyk, M., Blaszczyk, B., and Czuczwar, S. J. [Caffeine and antiepileptic drugs: experimental and clinical data]. Przegl.Lek. 2007;64(11):965-967. View abstract.
  • Joeres R, Klinker H, Heusler H, et al. Influence of mexiletine on caffeine elimination. Pharmacol Ther 1987;33:163-9. View abstract.
  • Joeres R, Richter E. Mexiletine and caffeine elimination. N Engl J Med 1987;317:117. View abstract.
  • Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl) 2004;176:1-29. View abstract.
  • Kim SY, Oh MR, Kim MG, Chae HJ, Chae SW. Anti-obesity effects of yerba mate (Ilex Paraguariensis): a randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med. 2015;15:338. View abstract.
  • Kockler DR, McCarthy MW, Lawson CL. Seizure activity and unresponsiveness after hydroxycut ingestion. Pharmacotherapy 2001;21:647-51.. View abstract.
  • Kot, M. and Daniel, W. A. Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. Pharmacol Rep. 2009;61(6):1216-1220. View abstract.
  • Kynast-Gales SA, Massey LK. Effect of caffeine on circadian excretion of urinary calcium and magnesium. J Am Coll Nutr. 1994;13:467-72. View abstract.
  • Lake CR, Rosenberg DB, Gallant S, et al. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther 1990;47:675-85. View abstract.
  • Lane JD, Barkauskas CE, Surwit RS, Feinglos MN. Caffeine impairs glucose metabolism in type 2 diabetes. Diabetes Care 2004;27:2047-8. View abstract.
  • Leson CL, McGuigan MA, Bryson SM. Caffeine overdose in an adolescent male. J Toxicol Clin Toxicol 1988;26:407-15. View abstract.
  • Lloyd T, Johnson-Rollings N, Eggli DF, et al. Bone status among postmenopausal women with different habitual caffeine intakes: a longitudinal investigation. J Am Coll Nutr 2000;19:256-61. View abstract.
  • Luszczki, J. J., Zuchora, M., Sawicka, K. M., Kozinska, J., and Czuczwar, S. J. Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. Pharmacol Rep. 2006;58(5):652-659. View abstract.
  • Massey LK, Whiting SJ. Caffeine, urinary calcium, calcium metabolism and bone. J Nutr 1993;123:1611-4. View abstract.
  • Massey LK. Is caffeine a risk factor for bone loss in the elderly? Am J Clin Nutr 2001;74:569-70. View abstract.
  • Mattila ME, Mattila MJ, Nuotto E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol Toxicol 1992;70:286-9. View abstract.
  • Mattila MJ, Nuotto E. Caffeine and theophylline counteract diazepam effects in man. Med Biol 1983;61:337-43. View abstract.
  • Mattila MJ, Palva E, Savolainen K. Caffeine antagonizes diazepam effects in man. Med Biol 1982;60:121-3. View abstract.
  • Mattila MJ, Vainio P, Nurminen ML, et al. Midazolam 12 mg is moderately counteracted by 250 mg caffeine in man. Int J Clin Pharmacol Ther 2000;38:581-7. View abstract.
  • May DC, Jarboe CH, VanBakel AB, Williams WM. Effects of cimetidine on caffeine disposition in smokers and nonsmokers. Clin Pharmacol Ther 1982;31:656-61. View abstract.
  • Mays, D. C., Camisa, C., Cheney, P., Pacula, C. M., Nawoot, S., and Gerber, N. Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. Clin.Pharmacol.Ther. 1987;42(6):621-626. View abstract.
  • McGee J, Patrick RS, Wood CB, Blumgart LH. A case of veno-occlusive disease of the liver in Britain associated with herbal tea consumption. J Clin Pathol 1976;29:788-94. View abstract.
  • Mohiuddin, M., Azam, A. T., Amran, M. S., and Hossain, M. A. In vive effects of gliclazide and metformin on the plasma concentration of caffeine in healthy rats. Pak.J Biol Sci 5-1-2009;12(9):734-737. View abstract.
  • Morris JC, Beeley L, Ballantine N. Interaction of ethinyloestradiol with ascorbic acid in man [letter]. Br Med J (Clin Res Ed) 1981;283:503. View abstract.
  • Nix D, Zelenitsky S, Symonds W, et al. The effect of fluconazole on the pharmacokinetics of caffeine in young and elderly subjects. Clin Pharmacol Ther 1992;51:183.
  • Norager, C. B., Jensen, M. B., Weimann, A., and Madsen, M. R. Metabolic effects of caffeine ingestion and physical work in 75-year old citizens. A randomized, double-blind, placebo-controlled, cross-over study. Clin Endocrinol (Oxf) 2006;65(2):223-228. View abstract.
  • Nurminen ML, Niittynen L, Korpela R, Vapaatalo H. Coffee, caffeine and blood pressure: a critical review. Eur J Clin Nutr 1999;53:831-9. View abstract.
  • Ochiai R, Jokura H, Suzuki A, et al. Green coffee bean extract improves human vasoreactivity. Hypertens Res 2004;27:731-7. View abstract.
  • Petrie HJ, Chown SE, Belfie LM, et al. Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss. Am J Clin Nutr 2004;80:22-8. View abstract.
  • Pintos J, Franco EL, Oliveira BV, et al. Mate, coffee, and tea consumption and risk of cancers of the upper aerodigestive tract in southern Brazil. Epidemiology 1994;5:583-90. View abstract.
  • Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 1999;39:936-40. View abstract.
  • Raaska K, Raitasuo V, Laitila J, Neuvonen PJ. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol 2004;94:13-8. View abstract.
  • Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 2001;74:694-700. View abstract.
  • Robinson LE, Savani S, Battram DS, et al. Caffeine ingestion before an oral glucose tolerance test impairs blood glucose management in men with type 2 diabetes. J Nutr 2004;134:2528-33. View abstract.
  • Saldana MD, Zetzl C, Mohamed RS, Brunner G. Extraction of methylxanthines from guarana seeds, mate leaves, and cocoa beans using supercritical carbon dioxide and ethanol. J Agric Food Chem 2002;50:4820-6. View abstract.
  • Sanderink GJ, Bournique B, Stevens J, et al. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. Pharmacol Exp Ther 1997;282:1465-72. View abstract.
  • Santos IS, Matijasevich A, Valle NC. Mate drinking during pregnancy and risk of preterm and small for gestational age birth. J Nutr 2005;135:1120-3. View abstract.
  • Sewram V, De Stefani E, Brennan P, Boffetta P. Mate consumption and the risk of squamous cell esophageal cancer in uruguay. Cancer Epidemiol Biomarkers Prev 2003;12:508-13. View abstract.
  • Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J Nutr 1996;126:1181S-6S. View abstract.
  • Shet, M. S., McPhaul, M., Fisher, C. W., Stallings, N. R., and Estabrook, R. W. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997;25(11):1298-1303. View abstract.
  • Sinclair CJ, Geiger JD. Caffeine use in sports. A pharmacological review. J Sports Med Phys Fitness 2000;40:71-9. View abstract.
  • Smith A. Effects of caffeine on human behavior. Food Chem Toxicol 2002;40:1243-55. View abstract.
  • Stanek EJ, Melko GP, Charland SL. Xanthine interference with dipyridamole-thallium-201 myocardial imaging. Pharmacother 1995;29:425-7. View abstract.
  • Stefani ED, Moore M, Aune D, Deneo-Pellegrini H, Ronco AL, Boffetta P, et al. Maté consumption and risk of cancer: a multi-site case-control study in Uruguay. Asian Pac J Cancer Prev. 2011;12(4):1089-93. View abstract.
  • Stille, W., Harder, S., Mieke, S., Beer, C., Shah, P. M., Frech, K., and Staib, A. H. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J.Antimicrob.Chemother. 1987;20(5):729-734. View abstract.
  • Stookey JD. The diuretic effects of alcohol and caffeine and total water intake misclassification. Eur J Epidemiol 1999;15:181-8. View abstract.
  • The National Toxicology Program (NTP). Caffeine. Center for the Evaluation of Risks to Human Reproduction (CERHR). Available at: http://cerhr.niehs.nih.gov/common/caffeine.html.
  • Underwood DA. Which medications should be held before a pharmacologic or exercise stress test? Cleve Clin J Med 2002;69:449-50. View abstract.
  • Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for bodybuilding. J Neurol Neurosurg Psychiatr 2000;68:112-3. View abstract.
  • Vandeberghe K, Gillis N, Van Leemputte M, et al. Caffeine counteracts the ergogenic action of muscle creatine loading. J Appl Physiol 1996;80:452-7. View abstract.
  • Vaz, J., Kulkarni, C., David, J., and Joseph, T. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers. Indian J.Exp.Biol. 1998;36(1):112-114. View abstract.
  • Wahllander A, Paumgartner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol 1989;37:279-83. View abstract.
  • Wallach J. Interpretation of Diagnostic Tests. A synopsis of Laboratory Medicine. Fifth ed; Boston, MA: Little Brown, 1992.
  • Watson JM, Jenkins EJ, Hamilton P, et al. Influence of caffeine on the frequency and perception of hypoglycemia in free-living patients with type 1 diabetes. Diabetes Care 2000;23:455-9. View abstract.
  • Watson JM, Sherwin RS, Deary IJ, et al. Dissociation of augmented physiological, hormonal and cognitive responses to hypoglycaemia with sustained caffeine use. Clin Sci (Lond) 2003;104:447-54. View abstract.
  • Wemple RD, Lamb DR, McKeever KH. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. Int J Sports Med 1997;18:40-6. View abstract.
  • Williams MH, Branch JD. Creatine supplementation and exercise performance: an update. J Am Coll Nutr 1998;17:216-34. View abstract.
  • Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC. Habitual caffeine intake and the risk of hypertension in women. JAMA 2005;294:2330-5. View abstract.
  • Yu S, Yue SW, Liu Z, Zhang T, Xiang N, Fu H. Yerba mate (Ilex paraguariensis) improves microcirculation of volunteers with high blood viscosity: a randomized, double-blind, placebo-controlled trial. Exp Gerontol. 2015;62:14-22. View abstract.
  • Zelenitsky SA, Norman A, Nix DE. The effects of fluconazole on the pharmacokinetics of caffeine in young and elderly subjects. J Infect Dis Pharmacother 1995;1:1-11.
  • Zhang LL, Zhang JR, Guo K, et al. Effects of fluoroquinolones on CYP4501A and 3A in male broilers. Res Vet Sci 2011;90:99-105. View abstract.
  • Zheng XM, Williams RC. Serum caffeine levels after 24-hour abstention: clinical implications on dipyridamole (201)Tl myocardial perfusion imaging. J Nucl Med Technol 2002;30:123-7. View abstract.

More Resources for YERBA MATE

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.